

# **US - OSHA SAFETY DATA SHEET**

Issue Date 14MAR2017 Revision Date 04-MAR-2022 Version 5

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

**Product identifier** 

Product Name VAXELIS<sup>TM</sup>

Other means of identification

**Product Information** Single-dose vial in packages of 10 vials

Single-dose syringe in packages of 10 syringes

**Synonyms** 

Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus,

Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B

[Recombinant] Vaccine

Recommended use of the chemical and restrictions on use

**Recommended Use** Active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and

invasive disease due to Haemophilus influenzae type b in children from 6 weeks through 4

years of age (prior to the 5th birthday).

Uses advised against Not available.

Details of the supplier of the safety data sheet

Supplier Address Sanofi Pasteur 1 Discovery Drive Swiftwater, PA 18370

#### **Emergency telephone number**

24 Hour Emergency Phone Number 1-703-741-5970 / 1-800-424-9300 CCN # 2118 (CHEMTREC)

### 2. HAZARDS IDENTIFICATION

#### Classification

#### **Health Hazards**

Not classified.

### **Physical hazards**

Not classified.

#### **OSHA Regulatory Status**

This product is a vaccine that is safe for consumers when used according to the label directions. Potential hazards that may occur if product is not used according to the consumer label are as follows throughout the sheet.

### **Label elements**

### **Emergency Overview**

Normal precautions common to safe manufacturing practice should be followed in handling and storage.

Appearance White, cloudy suspension. Physical state Liquid Odor Not available.

### Hazards not otherwise classified (HNOC)

Not classified as a hazardous substance.

#### 3. COMPOSITION/INFORMATION ON INGREDIENTS

**Synonyms** 

Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine)

Chemical Name	CAS No.	Weight-%
Diphtheria Toxoid Adsorbed	N/A	N/A
Tetanus Toxoid Adsorbed	N/A	N/A
Filamentous Haemagglutinin Adsorbed (FHA)	N/A	0.001
Fimbriae Types 2 and 3 Adsorbed (FIM)	N/A	0.001
Pertactin Adsorbed	N/A	0.0006
Pertussis Adsorbed	N/A	0.002
Inactivated Poliomyelitis virus concentrate	N/A	N/A
Polyribosylribitol phosphate (PRP) of Haemophilus influenzae type b	N/A	N/A
Hepatitis B surface antigen (HBsAg)	N/A	N/A
Outer membrane protein complex (OMPC) of Neisseria meningitidis	N/A	N/A
Water	7732-18-5	q.s to 100

Note: Ingredients below reportable levels are not listed.

#### 4. FIRST AID MEASURES

First aid measures

Eye contact In case of eye contact, immediately flush eyes with fresh water for at least 15 minutes while

holding the eyelids open. Remove contact lenses if worn. Get medical attention if irritation

persists.

**Skin Contact** In case of contact, remove contaminated clothing. Immediately flush skin with copious

amounts of water for at least 15 minutes. Obtain medical attention if skin reaction occurs.

In case of inhalation, remove to fresh air. If breathing is difficult, administer oxygen. Seek

medical attention immediately.

**Ingestion** In case of accidental ingestion, wash out mouth with copious amounts of water. Seek

medical attention if needed. Do not induce vomiting unless directed by medical personnel.

Never give anything by mouth to an unconscious person.

**Self-protection of the first aider** Do not use mouth-to-mouth method if victim ingested or inhaled the substance; give

artificial respiration with the aid of a pocket mask equipped with a one-way valve or other

proper respiratory medical device.

Most important symptoms and effects, both acute and delayed

Symptoms Common effects of the vaccine include the following: fussiness/irritability; inconsolable

crying; decreased activity/lethargy; fever.

Indication of any immediate medical attention and special treatment needed

### 5. FIRE-FIGHTING MEASURES

#### Suitable extinguishing media

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media None known.

#### Specific hazards arising from the chemical

Not available.

Hazardous combustion products Not available.

**Explosion data** 

Sensitivity to Mechanical Impact Not available. Sensitivity to Static Discharge None known.

#### Protective equipment and precautions for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

**Personal precautions** Wear appropriate personal protective equipment (see Section 8).

**Environmental precautions** 

**Environmental precautions** See Section 12 for additional ecological information.

Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Wipe up with absorbent material (e.g. cloth) for disposal. Area where spill occurred can be

cleaned with the regular cleaning materials designated for the area.

### 7. HANDLING AND STORAGE

Precautions for safe handling

Advice on safe handling Handle in accordance with good industrial hygiene and safety practice.

Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store at 2° to 8°C (35° to 46°F). Do not freeze.

Incompatible materials Not available.

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

**Control parameters** 

**Exposure Guidelines**This product, as supplied, does not contain any hazardous materials with Occupational

Exposure Limits (OEL) established by the region specific regulatory bodies.

Appropriate engineering controls

Engineering Controls Used as supplied, no special engineering controls are needed when administering the

vaccine.

Individual protection measures, such as personal protective equipment

**Eye/face protection** In laboratory or industrial settings, safety glasses with side shields are recommended.

**Skin and body protection** In laboratory or industrial settings, gloves and lab coats are recommended.

**Respiratory protection**Used as supplied, general room ventilation is acceptable and no special respiratory

protection is needed when administering the vaccine.

General Hygiene Considerations Always observe good personal hygiene measures, such as washing after handling the

material and before eating, drinking, and/or smoking. Routinely wash work clothing and

protective equipment.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Physical state Liquid

AppearanceCloudy suspension.OdorNot available.ColorWhite.Odor thresholdNot available.

Property Values Remarks • Method

pHNot available.Melting point/freezing pointNot available.Boiling point / boiling rangeNot available.Flash pointNot available.Evaporation rateNot available.Flammability (solid, gas)Not available.

Flammability Limit in Air

**Upper flammability limit:** Not available. Lower flammability limit: Not available. Vapor pressure Not available. Vapor density Not available. **Specific Gravity** Not available. Water solubility Not available. Solubility in other solvents Not available. **Partition coefficient** Not available. **Autoignition temperature** Not available. **Decomposition temperature** Not available. Kinematic viscosity Not available. **Dynamic viscosity** Not available. **Explosive properties** Not available. **Oxidizing properties** Not available.

**Other Information** 

Softening point
Molecular weight
VOC Content (%)
Density
Not available.
Not available.
Not available.
Not available.
Not available.
Not available.

## 10. STABILITY AND REACTIVITY

#### Reactivity

Not reactive under normal conditions.

#### **Chemical stability**

Stable under normal conditions.

### **Possibility of Hazardous Reactions**

None under normal handling.

**Hazardous polymerization** Hazardous polymerization does not occur.

### **Conditions to avoid**

Not available.

#### **Incompatible materials**

Not available.

## **Hazardous Decomposition Products**

None under normal use conditions.

#### 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Product Information No data available.

**Inhalation** No impact known or expected under normal use.

**Eye contact** No impact known or expected under normal use.

**Skin Contact** No impact known or expected under normal use.

**Ingestion** No impact known or expected under normal use.

Information on toxicological effects

Symptoms Common effects of the vaccine include the following: fussiness/irritability; inconsolable

crying; decreased activity/lethargy/somnolence; site pain, erythema and/or swelling; fever;

decreased appetite; vomiting

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritation
Serious eye damage/eye irritation
Irritation
Corrosivity
Sensitization
Not available.
Not available.
Not available.
Not available.
Not available.

Germ cell mutagenicity

Carcinogenicity

VAXELIS™ vaccine has not been evaluated for mutagenic potential.

VAXELIS™ vaccine has not been evaluated for carcinogenic potential.

Reproductive toxicity Animal reproduction studies have not been conducted with VAXELIS™ vaccine. It is also

not known whether VAXELIS™ vaccine can cause fetal harm when administered to a

pregnant woman or can affect reproductive capacity.

**Developmental Toxicity** Not available. **Teratogenicity** Not available. STOT - single exposure Not classified. STOT - repeated exposure Not classified. **Chronic toxicity** Not available. Subchronic toxicity Not available. **Target Organ Effects** Not available. **Neurological effects** Not available. Other adverse effects Not available. **Aspiration hazard** Not available.

## 12. ECOLOGICAL INFORMATION

## **Ecotoxicity**

Not available.

## Persistence and degradability

Not available.

### **Bioaccumulation**

Not available.

#### **Mobility**

Not available.

Other adverse effects Not available.

### 13. DISPOSAL CONSIDERATIONS

Waste treatment methods

Disposal of wastes Disposal should be in accordance with applicable regional, national and local laws and

regulations.

Contaminated packaging Disposal should be in accordance with applicable regional, national and local laws and

regulations.

US EPA Waste Number Not applicable.

California Hazardous Waste Codes Not applicable.

### 14. TRANSPORT INFORMATION

**DOT** Not regulated.

TDG Not regulated.

MEX Not regulated.

ICAO (air) Not regulated.

IATA Not regulated.

IMDG Not regulated.

RID Not regulated.

ADR Not regulated.

ADN Not regulated.

# 15. REGULATORY INFORMATION

# **US Federal Regulations**

# **SARA 313**

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

#### SARA 311/312 Hazard Categories

Acute health hazard No
Chronic Health Hazard No
Fire hazard No
Sudden release of pressure hazard No
Reactive Hazard No

## **CWA (Clean Water Act)**

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

#### **CERCLA**

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355).

### **US State Regulations**

### **California Proposition 65**

Component (Formaldehyde) is on Proposition 65 list; however, based on percentage of formulation it is not considered hazardous.

Component (Neomycin) is on Proposition 65 list: however, based on percentage of formulation it is not considered hazardous.

## U.S. State Right-to-Know Regulations

This product does not contain any substances regulated by state right-to-know regulations.

#### **U.S. EPA Label Information**

EPA Pesticide Registration Number Not applicable.

## **16. OTHER INFORMATION**

Revision Date 04-MAR-2022

Revision Note Updated Product Information. Revised by Sanofi Pasteur.

#### Disclaimer

Sanofi Pasteur considers that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. The information contained herein is designated only as guidance for safe handling, storage and use of the substance and is not a specification nor does it guarantee any specific properties. Only competent personnel, within a controlled environment should handle all chemicals. Sanofi Pasteur cannot be held liable for any loss, injury or damage from contact with the product.

**End of Safety Data Sheet**